网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
血清Vaspin、ATGL水平与老年患者冠心病危险因素及严重程度的相关性
作者:杨明琦1  刘妍妍2 
单位:1. 哈尔滨医科大学附属第一医院 门诊部办公室, 黑龙江 哈尔滨 150001;
2. 哈尔滨医科大学 转化中心办公室, 黑龙江 哈尔滨 150081
关键词:内脏脂肪组织特异性丝氨酸蛋白酶抑制因子 脂肪甘油三酯脂肪酶 老年患者 冠心病 危险因素 相关性 
分类号:R541.4
出版年·卷·期(页码):2018·46·第四期(402-406)
摘要:

目的:探讨血清特异性丝氨酸蛋白酶抑制因子(Vaspin)、脂肪甘油三酯脂肪酶(ATGL)水平与老年患者冠心病(CHD)危险因素及严重程度的相关性。方法:选取CHD患者(CHD组)124例和健康体检者(NC组)80例,收集两组入院时的基线资料,于入院后第2天检测CHD相关血液学指标;并于入院3 d内行冠状动脉造影,以Gensini积分评价冠状动脉狭窄程度,NC组记录除Gensini积分外其他指标,统计并分析结果。结果:(1)CHD组收缩压、舒张压、体重、体质指数(BMI)、吸烟指数、饮酒指数、食盐日摄入量均高于NC组。(2)CHD组Vaspin、ATGL水平、出凝血指标国际标准化比值(INR)、高密度脂蛋白胆固醇(HDL-C)水平低于NC组,纤维蛋白原(FIB)、胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、脂蛋白a[Lp(a)]、血糖水平高于NC组。NC组无明显冠脉狭窄,CHD组改良Gensini积分为22.86±8.09。(3)Vaspin、ATGL与收缩压、舒张压、体重、BMI、吸烟指数、饮酒指数及食盐摄入呈负相关(P<0.05)。(4)Vaspin、ATGL与FIB、TC、TG、LDL-C、Lp(a)、血糖水平及Gensini积分呈负相关(P<0.05),与INR、HDL-C水平呈正相关(P<0.05)。结论:Vaspin、ATGL与老年患者CHD危险因素及CHD严重程度密切相关,CHD危险因素可能导致或加重机体糖、脂代谢及凝血系统紊乱,从而影响Vaspin、ATGL水平;Vaspin、ATGL可能作为一种保护性因子,参与机体代谢平衡的维持。

Objective: To investigate the relationship between serum specific serine protease inhibitor(Vaspin), adipose triglyceride lipase(ATGL) and risk factors and severity of coronary heart disease(CHD) in elderly patients. Methods: One hundred and twenty-four CHD patients(CHD group) and 80 healthy subjects(NC group) were selected. The clinical data of the two groups were collected. CHD-related hematological parameters were measured on the second day after admission. Coronary angiography was performed to assess the extent of coronary artery stenosis with Gensini score. Other indicators were recorded in the NC group except Gensini score and the results were then analyzed. Results: (1) The systolic blood pressure, diastolic blood pressure, body weight, BMI, smoking index, alcohol index, salt intake in CHD group were higher than those in NC group(P<0.05). (2) Vaspin, ATGL, INR, HDL-C of CHD group were lower than those of the NC group(P<0.05).The levels of FIB, TC, TG, LDL-C, Lp(a), blood glucose in CHD group were higher than those of NC group(P<0.05). No obvious coronary stenosis was found in NC group, and the improved Gensini score was 22.86±8.09 in CHD group. (3) Levels of Vaspin and ATGL were negatively correlated with systolic blood pressure, diastolic blood pressure, body weight, BMI, smoking index, drinking index and salt intake(P<0.05). (4) Vaspin and ATGL were negatively correlated with FIB, TC, TG, LDL-C, Lp(a), blood glucose, Gensini score(P<0.05),but positively correlated with INR and HDL-C(P<0.05). Conclusion: Vaspin and ATGL are closely related to the risk factors and the severity of coronary heart disease. Coronary heart disease risk factors may cause or aggravate the system disorder of body's sugar, lipid metabolism and coagulation, which may affect Vaspin and ATGL levels. Vaspin and ATGL may be a protective factor participating in the maintenance of metabolic balance.

参考文献:

[1] 张琳,王馨,张晓东,等.冠心病患者视黄醇结合蛋白4及丝氨酸蛋白酶抑制剂水平分析[J].中国药物与临床,2016,16(7):947-950.
[2] 陈磊磊,王泽穆,陈波,等.脂肪因子Vaspin表达水平与冠心病的相关性[J].江苏医药,2014,40(24):2981-2984.
[3] KARBEK B,BOZKURT N C,TOPALOGLU O,et al.Relationship of vaspin and apelin levels with insulin resistance and atherosclerosis in metabolic syndrome[J].Minerva Endocrinologica,2014,39(2):99-105.
[4] HUO Y,LIU S X,SONG G Y,et al.Plasma levels and placental expression of vaspin in pregnant women with diabetes mellitus[J].Braz J Med Biol Res,2015,48(3):273-279.
[5] 陈磊磊,王泽穆,陈波,等.脂肪因子Vaspin表达水平与冠心病的相关性[J].江苏医药,2014,40(24):2981-2984.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[7] 张爽,袁杰.糖代谢异常与冠心病关系的研究现状[J].东南大学学报:医学版,2016,35(4):602-606.
[8] 衡卫军,卢姗,马向华,等.吸烟指数与新发2型糖尿病动脉粥样硬化相关因素的研究[J].南京医科大学学报:自然科学版,2013,33(11):1597-1599.
[9] 王强,宫剑滨,张启高,等.血浆脂肪细胞因子与冠心病及糖尿病的相关性研究[J].中华实用诊断与治疗杂志,2014,27(6):551-553.
[10] HEIKER J T,KLOTING N,KOVACS P,et al.Vaspin inhibits kallikrein 7 by serpin mechanism[J].Cell Mol Life Sci,2013,70(14):2569-2583.
[11] 肖园园,曾朝阳,田晓年,等.新诊断2型糖尿病患者内脂素、vaspin与颈动脉粥样硬化的相关性[J].临床内科杂志,2013,30(1):697-699.
[12] 李海玲,彭文辉,崔世涛,等.血浆vaspin浓度与不稳定型心绞痛的相关性研究[J].临床心血管病杂志,2011,27(7):514-518.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 748342 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541